Allist Pharmaceuticals, Inc.

This early-stage study tests a drug called furmonertinib in 30 people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). Some participants have already tried other treatments, while others are new to therapy. The goal is to see how wel…

This study tests an experimental drug called JAB-21822 (glecirasib) in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and can shrink tumors. About 315 adults whose cancer has not responded to standard treatments w…

This study tests a daily pill called furmonertinib in about 100 people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). Participants must have already tried platinum chemotherapy. The goal is to see if the drug shrinks tumors and how…

This study tests a combination of two drugs, JAB-21822 and cetuximab, in people with advanced colorectal, small intestine, or appendiceal cancers that have a specific KRAS G12C mutation. The goal is to see if the combo is safe and can shrink tumors. About 48 adults who have alrea…